Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company s most advanced program is talactoferrin, an oral immunotherapy that has demonstrated activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non small cell lung cancer, and a Phase II/III trial with talactoferrin in severe sepsis is underway. Other clinical development programs include RGB , a multi targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany Princeton, New Jersey and Houston, Texas.
Quote | Agennix Ag Ord (OTCMKTS:GAGXF)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.00001 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 10/10/2019 04:47:53 pm |
News | Agennix Ag Ord (OTCMKTS:GAGXF)
Message Board Posts | Agennix Ag Ord (OTCMKTS:GAGXF)
Subject | By | Source | When |
---|---|---|---|
SpecPol: Should be an exciting year | SpecPol | investorshangout | 08/02/2017 2:36:02 PM |
Stock_Tracker: Latest Gbc Biotech (GAGXF) Headlines Global Sepsis Clinical Trials Review Report - H2 | Stock_Tracker | investorshangout | 03/10/2014 2:40:01 AM |
chartguy89: GAGXF 0.12 Stock Charts $GAGXF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 2:31:30 PM |
chartguy89: GAGXF Stock Charts Last: +0.0118 Wednesday, February 26, 2014 at 8:41:52 AM $GAGXF | chartguy89 | investorshangout | 02/26/2014 1:42:04 PM |